Xiangning Huang

Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery.

A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery.

Journal: Future oncology (London, England)

Published: April 27, 2026

Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.

Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 05, 2026

Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort.

Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 04, 2025

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 02, 2025

A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer.

A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer.

Journal: Future oncology (London, England)

Published: March 07, 2025

Population Pharmacokinetics of Osimertinib in Patients With Non-Small Cell Lung Cancer.

Population Pharmacokinetics of Osimertinib in Patients With Non-Small Cell Lung Cancer.

Journal: Pharmacology research & perspectives

Published: November 28, 2024

EGFR mutation testing across the osimertinib clinical program.

EGFR mutation testing across the osimertinib clinical program.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 07, 2024

Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study.

Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 21, 2024

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.

Journal: The New England journal of medicine

Published: June 03, 2024

Exposure-response modelling of osimertinib in patients with non-small cell lung cancer.

Exposure-response modelling of osimertinib in patients with non-small cell lung cancer.

Journal: British journal of clinical pharmacology

Published: December 15, 2023

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 02, 2023

Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis.

Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis.

Journal: JTO clinical and research reports

Published: June 02, 2023

Showing 1-12 of 21

Last Updated: 09/26/2026